450:. In September 2021, further results were presented by Dr. Matthias Liechti, head of the Liechti Lab, at the INSIGHT Conference in Berlin. The results included the first clinical evidence on the comparative effects of LSD and psilocybin, stating 100mcg of LSD produced the same acute perceptual effects as a dose of 20 mg of psilocybin in healthy volunteers. Additionally, psilocybin taken after administering antidepressants for two weeks prior, was deemed safe, as well as reduced anxiety and blood pressure without hindering the psychedelic experience.
27:
440:, and clinical trials combining MDMA and LSD were announced. A study to better understand and compare the altered states of consciousness induced by psilocybin and LSD began in August 2020, and in October a Phase 1 study at the Liechti Lab on the acute dose dependent effects of LSD was completed. The results of the study were published by the
358:
clinical trial to enable further clinical trials targeting opioid withdrawal and opioid use disorder. Psychopharmacologist
Stanley Glick, who first synthesized 18-MC with chemist Martin E. Kuehne, was later named to MindMed's board of directors and appointed chair of its scientific advisory board.
432:, and other psychedelic substances. The development of a novel compound designed to shorten the duration or stop an LSD experience that would allow LSD to be more widely used in a therapeutic environment was subsequently announced. Later that year a clinical trial studying the effects of
477:
in healthy subjects was safe at the doses tested. It was subsequently announced that pending review of the data from the first round of tests, MindMed would initiate a Phase 2a proof of concept study with escalatad dosages of
982:
Holze, Friederike; Vizeli, Patrick; Ley, Laura; Müller, Felix; Dolder, Patrick; Stocker, Melanie; Duthaler, Urs; Varghese, Nimmy; Eckert, Anne; Borgwardt, Stefan; Liechti, Matthias E. (2020-10-15).
651:
1144:
1174:
1139:
1149:
409:
and research to advance and deploy psychedelic medicines. The company committed $ 5 million to establish the center, which will also explore 18-MC and the use of drugs, including
331:
to improve focus after struggling with his own mental health and addiction issues, spent two years researching the therapeutic potential of psychedelics prior to meeting Hurst.
702:"A startup that wants to use psychedelics to treat addiction just raised $ 6.2 million from the host of Shark Tank and the architect behind the world's biggest cannabis grower"
457:
in the
Netherlands. The university provided facilities and personnel for a Phase 1 study to evaluate the effects of two low doses of LSD on mood, sleep and neuroplasticity.
1056:
1159:
86:
441:
900:
801:
751:
1164:
1169:
957:
850:
701:
1070:
927:
1154:
500:
327:, and Stephen Hurst, a 35-year veteran of the pharmaceutical industry. Rahn, who was interested in the Silicon Valley trend of psychedelic
1091:
675:
532:
1134:
390:
446:
564:
351:
876:
393:
Robert Barrow. On
January 7th, 2022, Co-Founder Stephen Hurst resigned from his position on the company's board of directors.
984:"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects"
355:
193:
385:
In a press release on June 9th, 2021 MindMed announced that Jamon Rahn was stepping down both as the CEO and as a
421:
826:
266:
72:
207:
186:
474:
473:
Project Layla: A study concluding that a Phase 1 clinical trial of single and multiple ascending doses of
433:
343:
593:
375:
1039:
652:"This New York City Pharma Startup Wants To Turn LSD Into An FDA-Approved Medicine For Anxiety Disorder"
454:
200:
229:
726:
303:-based biotechnology company that is currently developing clinical and therapeutic applications for
406:
339:
234:
402:
386:
260:
1021:
1003:
540:
379:
335:
1011:
995:
630:
367:
304:
224:
308:
350:. In June 2019, it acquired the 18-MC drug development program, previously funded by the
1016:
983:
37:
453:
In
December 2020, MindMed entered into an investigator-sponsored study agreement with
362:
MindMed was the first psychedelic pharmaceutical company to go public, listing on the
1128:
1057:"MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration"
775:
300:
155:
107:
103:
67:
58:
45:
370:
with the
Canadian gold mining company Broadway Gold Mining. It began trading on the
76:
901:"NYU Langone, MindMed team up to launch training program for psychedelic therapies"
363:
320:
676:"Addiction Treatment Gets Psychedelic With 'Shark Tank' Investor-Approved Startup"
92:
328:
54:
999:
414:
410:
293:
254:
1007:
544:
466:
Project Lucy: Therapist-led experiential therapy incorporating microdoses of
437:
1025:
928:"Psychedelic DMT to Enter Clinical Trials | Drug Discovery And Development"
635:
618:
26:
1071:"Mind Medicine announces study evaluating LSD microdosing | Healthing.ca"
776:"Developing a Drug Based on Ibogaine for the Opioid Crisis - DoubleBlind"
347:
565:"Why Magic Mushrooms Are The Next Big Booming (and Legal!) Drug Market"
129:
424:, gaining rights to more than ten years of the lab's data related to
420:
In April 2020, the company entered into a long-term partnership with
371:
63:
346:, a non-hallucinogenic molecule based on the psychoactive alkaloid
1092:"Forget Xanax. This Company Wants You to Take a Large Dose of LSD"
802:"Psychedelic Drug Company MindMed Applies For Nasdaq Up-Listing"
752:"Psychedelic Drug Company MindMed Applies For Nasdaq Up-Listing"
429:
405:
to launch a clinical training program to train psychiatrists in
324:
467:
425:
958:"Why Investing in Psychedelics Could be Better than Cannabis"
533:"Psychedelics-Drug Startup Raises $ 24 Million Ahead of IPO"
401:
In March 2020, MindMed announced that it had partnered with
1119:
354:, and in September began to prepare 18-MC for a Phase I
877:"Stephen Hurst Resigns from MindMed Board of Directors"
334:
MindMed initially focused on developing treatments for
851:"MindMed Announces Chief Executive Officer Transition"
278:
501:"Psychedelics Company MindMed Trips In Nasdaq Debut"
273:
253:
243:
217:
176:
166:
150:
136:
113:
99:
85:
43:
33:
374:as MNMD in April 2021 after being approved for an
1145:Medical technology companies of the United States
1051:
1049:
319:MindMed was founded in May 2019 by Jamon Rahn, a
1175:Companies listed on the Frankfurt Stock Exchange
1140:Health care companies based in New York (state)
922:
920:
494:
492:
1040:"Liechti Lab | Department of Biomedicine"
1150:Pharmaceutical companies of the United States
8:
19:
442:American College of Neuropsychopharmacology
951:
949:
947:
25:
18:
1015:
634:
587:
585:
436:, the primary psychoactive ingredient in
827:"MindMed To Commence Trading on Nasdaq"
488:
422:University Hospital Basel's Liechti Lab
1160:American companies established in 2019
619:"The promise of psychedelic research"
526:
524:
522:
520:
7:
531:Ramachandran, Shalini (2020-02-27).
16:Psychedelic medicine biotech company
956:Chang, Ellen (September 20, 2020).
725:Today, Psychedelics (2019-04-22).
14:
617:Peritore, Carina S (2022-03-01).
592:Heller, Nathan (3 October 2020).
727:"The Future of Medical Ibogaine"
352:National Institute on Drug Abuse
1165:Companies listed on Cboe Canada
875:Hopkins, Jessica (2022-01-07).
1170:Companies listed on the Nasdaq
397:Partnerships with universities
1:
962:U.S. News & World Report
594:"Turn On, Tune In, Get Well"
290:Mind Medicine (MindMed) Inc.
235:Psychedelic assisted therapy
1155:Biopharmaceutical companies
855:Mind Medicine (MindMed) Inc
825:Gage, Collin (2021-04-23).
366:in March of 2020 through a
192:Miri Halperin Wernli, PhD (
20:Mind Medicine/MindMed, Inc.
1191:
1000:10.1038/s41386-020-00883-6
119:; 5 years ago
1135:Psychedelic drug research
389:, to be replaced by then
199:Daniel R Karlin, MD, MA (
24:
267:Perth, Western Australia
988:Neuropsychopharmacology
461:Ongoing clinical trials
447:Neuropsychopharmacology
413:-assisted therapy for
323:alumnus who worked at
636:10.4155/fdd-2021-0012
623:Future Drug Discovery
455:Maastricht University
407:psychedelic therapies
387:director on the board
364:Canadian NEO Exchange
415:alcohol use disorder
230:Psychedelic research
537:Wall Street Journal
340:opioid use disorder
307:and, more broadly,
245:Number of employees
21:
731:Psychedelics Today
470:to lessen anxiety.
265:MindMed Pty Ltd. (
261:Basel, Switzerland
259:MindMed Discover (
336:opioid withdrawal
309:psychoplastogenic
294:doing business as
287:
286:
206:Schond Greenway (
1182:
1107:
1106:
1104:
1103:
1088:
1082:
1081:
1079:
1078:
1067:
1061:
1060:
1059:(Press release).
1053:
1044:
1043:
1036:
1030:
1029:
1019:
979:
973:
972:
970:
968:
953:
942:
941:
939:
938:
924:
915:
914:
912:
911:
905:FierceHealthcare
897:
891:
890:
888:
887:
872:
866:
865:
863:
862:
847:
841:
840:
838:
837:
822:
816:
815:
813:
812:
800:Yakowicz, Will.
797:
791:
790:
788:
787:
772:
766:
765:
763:
762:
750:Yakowicz, Will.
747:
741:
740:
738:
737:
722:
716:
715:
713:
712:
706:Business Insider
697:
691:
690:
688:
687:
672:
666:
665:
663:
662:
650:Yakowicz, Will.
647:
641:
640:
638:
614:
608:
607:
605:
604:
589:
580:
579:
577:
576:
561:
555:
554:
552:
551:
528:
515:
514:
512:
511:
499:Yakowicz, Will.
496:
368:reverse takeover
283:
280:
225:Drug development
146:Leonard Latchman
140:Jamon "JR" Rahn
127:
125:
120:
95:
29:
22:
1190:
1189:
1185:
1184:
1183:
1181:
1180:
1179:
1125:
1124:
1116:
1111:
1110:
1101:
1099:
1090:
1089:
1085:
1076:
1074:
1069:
1068:
1064:
1055:
1054:
1047:
1038:
1037:
1033:
981:
980:
976:
966:
964:
955:
954:
945:
936:
934:
926:
925:
918:
909:
907:
899:
898:
894:
885:
883:
874:
873:
869:
860:
858:
849:
848:
844:
835:
833:
824:
823:
819:
810:
808:
799:
798:
794:
785:
783:
780:DoubleBlind Mag
774:
773:
769:
760:
758:
749:
748:
744:
735:
733:
724:
723:
719:
710:
708:
700:Brodwin, Erin.
699:
698:
694:
685:
683:
674:
673:
669:
660:
658:
649:
648:
644:
616:
615:
611:
602:
600:
591:
590:
583:
574:
572:
563:
562:
558:
549:
547:
530:
529:
518:
509:
507:
498:
497:
490:
485:
463:
444:in the journal
399:
317:
277:
264:
246:
239:
213:
185:Robert Barrow (
179:
169:
162:
158:
145:
143:
141:
123:
121:
118:
106:
91:
81:
48:
17:
12:
11:
5:
1188:
1186:
1178:
1177:
1172:
1167:
1162:
1157:
1152:
1147:
1142:
1137:
1127:
1126:
1123:
1122:
1115:
1114:External links
1112:
1109:
1108:
1083:
1062:
1045:
1031:
994:(3): 537–544.
974:
943:
916:
892:
867:
842:
817:
792:
767:
742:
717:
692:
667:
642:
609:
598:The New Yorker
581:
556:
516:
487:
486:
484:
481:
480:
479:
471:
462:
459:
398:
395:
316:
313:
285:
284:
275:
271:
270:
257:
251:
250:
247:
244:
241:
240:
238:
237:
232:
227:
221:
219:
215:
214:
212:
211:
204:
197:
190:
182:
180:
177:
174:
173:
170:
167:
164:
163:
160:
154:
152:
148:
147:
142:Stephen Hurst
138:
134:
133:
115:
111:
110:
101:
97:
96:
89:
83:
82:
80:
79:
70:
61:
51:
49:
44:
41:
40:
35:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
1187:
1176:
1173:
1171:
1168:
1166:
1163:
1161:
1158:
1156:
1153:
1151:
1148:
1146:
1143:
1141:
1138:
1136:
1133:
1132:
1130:
1121:
1118:
1117:
1113:
1098:. 4 June 2020
1097:
1093:
1087:
1084:
1072:
1066:
1063:
1058:
1052:
1050:
1046:
1041:
1035:
1032:
1027:
1023:
1018:
1013:
1009:
1005:
1001:
997:
993:
989:
985:
978:
975:
963:
959:
952:
950:
948:
944:
933:
929:
923:
921:
917:
906:
902:
896:
893:
882:
878:
871:
868:
856:
852:
846:
843:
832:
828:
821:
818:
807:
803:
796:
793:
781:
777:
771:
768:
757:
753:
746:
743:
732:
728:
721:
718:
707:
703:
696:
693:
681:
677:
671:
668:
657:
653:
646:
643:
637:
632:
628:
624:
620:
613:
610:
599:
595:
588:
586:
582:
570:
566:
560:
557:
546:
542:
538:
534:
527:
525:
523:
521:
517:
506:
502:
495:
493:
489:
482:
476:
472:
469:
465:
464:
460:
458:
456:
451:
449:
448:
443:
439:
435:
431:
427:
423:
418:
416:
412:
408:
404:
396:
394:
392:
388:
383:
381:
377:
373:
369:
365:
360:
357:
353:
349:
345:
341:
337:
332:
330:
326:
322:
314:
312:
310:
306:
302:
298:
295:
291:
282:
276:
272:
268:
262:
258:
256:
252:
248:
242:
236:
233:
231:
228:
226:
223:
222:
220:
216:
209:
205:
202:
198:
195:
191:
188:
184:
183:
181:
175:
171:
165:
157:
153:
149:
144:Scott Freeman
139:
135:
131:
117:May 2019
116:
112:
109:
108:Mental health
105:
104:Biotechnology
102:
98:
94:
90:
88:
84:
78:
74:
71:
69:
65:
62:
60:
56:
53:
52:
50:
47:
42:
39:
36:
32:
28:
23:
1100:. Retrieved
1096:www.vice.com
1095:
1086:
1075:. Retrieved
1073:. 2021-01-15
1065:
1034:
991:
987:
977:
967:November 16,
965:. Retrieved
961:
935:. Retrieved
931:
908:. Retrieved
904:
895:
884:. Retrieved
880:
870:
859:. Retrieved
857:. 2021-06-09
854:
845:
834:. Retrieved
830:
820:
809:. Retrieved
805:
795:
784:. Retrieved
782:. 2019-09-14
779:
770:
759:. Retrieved
755:
745:
734:. Retrieved
730:
720:
709:. Retrieved
705:
695:
684:. Retrieved
682:. 2019-12-17
679:
670:
659:. Retrieved
655:
645:
629:(1): FDD70.
626:
622:
612:
601:. Retrieved
597:
573:. Retrieved
571:. 2020-10-02
568:
559:
548:. Retrieved
536:
508:. Retrieved
504:
452:
445:
419:
400:
384:
361:
333:
321:Y-Combinator
318:
296:
289:
288:
255:Subsidiaries
151:Headquarters
93:CA60255C8850
34:Company type
1120:mindmed.co
403:NYU Langone
380:OTC Markets
329:microdosing
305:psychedelic
168:Area served
1129:Categories
1102:2021-02-10
1077:2021-02-08
937:2020-11-21
910:2020-11-23
886:2024-06-16
861:2024-06-16
836:2024-06-16
811:2020-11-23
786:2020-11-20
761:2020-11-19
736:2020-11-19
711:2020-11-20
686:2021-02-11
661:2020-11-19
603:2020-11-18
575:2020-11-17
550:2020-11-13
510:2021-05-31
483:References
411:psilocybin
178:Key people
1008:1740-634X
545:0099-9660
438:ayahuasca
378:from the
376:uplisting
194:president
172:Worldwide
46:Traded as
1026:33059356
932:LabRoots
680:Observer
569:Observer
348:ibogaine
301:New York
218:Services
156:New York
132:, Canada
100:Industry
1017:8027607
881:MindMed
831:MindMed
315:History
311:drugs.
299:, is a
297:MindMed
279:mindmed
274:Website
137:Founder
130:Toronto
124:2019-05
122: (
114:Founded
75::
66::
57::
1024:
1014:
1006:
806:Forbes
756:Forbes
656:Forbes
543:
505:Forbes
478:18-MC.
372:Nasdaq
64:Nasdaq
38:Public
475:18-MC
344:18-MC
342:with
128:, in
1022:PMID
1004:ISSN
969:2020
541:ISSN
430:MDMA
338:and
325:Uber
161:U.S.
87:ISIN
68:MNMD
59:MMED
1012:PMC
996:doi
631:doi
468:LSD
434:DMT
426:LSD
391:CDO
356:FDA
281:.co
208:CFO
201:CMO
187:CEO
77:MMQ
73:FWB
55:NEO
1131::
1094:.
1048:^
1020:.
1010:.
1002:.
992:46
990:.
986:.
960:.
946:^
930:.
919:^
903:.
879:.
853:.
829:.
804:.
778:.
754:.
729:.
704:.
678:.
654:.
625:.
621:.
596:.
584:^
567:.
539:.
535:.
519:^
503:.
491:^
428:,
417:.
382:.
292:,
249:57
159:,
1105:.
1080:.
1042:.
1028:.
998::
971:.
940:.
913:.
889:.
864:.
839:.
814:.
789:.
764:.
739:.
714:.
689:.
664:.
639:.
633::
627:4
606:.
578:.
553:.
513:.
269:)
263:)
210:)
203:)
196:)
189:)
126:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
